LifeArc, GVK BIO to celebrate a decade of partnership

Our Bureau Hyderabad | Updated on May 16, 2019 Published on May 16, 2019

GVK BIO, a Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, have announced the 10th anniversary of a successful partnership.

The collaboration brings together two organisations with a singular vision of advancing novel research ideas into potential medicines that can make a significant difference to patients.

Promising novel chemical entities discovered from this partnership have been either advanced by LifeArc into clinical development, or have been licensed out to leading global pharmaceutical companies, including a recently announced deal in neuroscience.

As the partnership evolved from a tactical relationship into a preferred partnership, the GVK BIO team has augmented LifeArc’s internal biology efforts, by supporting biochemical assays, carrying out drug metabolism and pharmacokinetics profiling studies, and soon, will be developing cell-based assays and running protein expression and purification studies.

“It has been our privilege to have collaborated with LifeArc and its world class team of scientists that have delivered medicines such as Keytruda, Tysabri, and Entyvio among others,” said Manni Kantipudi, Director and Chief Executive Officer, GVK BIO.

“The longevity of this partnership, and the transformative results of the collaboration, serve as a testament to the capabilities to make a difference in human life. We look forward to continuing this successful relationship with LifeArc in the coming years.”

Melanie Lee, Chief Executive Officer, LifeArc said “Our partnership with GVK BIO is a strong example of how shared goals and collaboration can create real value.”

Published on May 16, 2019
This article is closed for comments.
Please Email the Editor